Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia

Transfusion

Volumn 44, Issue 6, 2004, Pages 833-837

  Franchini, Massimo ^a   Gandini, Giorgio ^b   Veneri, Dino ^b   De Matteis, Giovanna ^b   Federici, Francesca ^b   Solero, Pietro ^b   Aprili, Giuseppe ^b  

^a OSPEDALE POLICLINICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ADULT; ARTICLE; BLOOD TRANSFUSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENE; GENE MUTATION; HEMOCHROMATOSIS; HH GENE; HUMAN; IRON DEPLETION; IRON OVERLOAD; MALE; PATIENT COMPLIANCE; PHLEBOTOMY; SAFETY;

ADULT; BLOOD TRANSFUSION; FEASIBILITY STUDIES; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; ITALY; LEUKEMIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHLEBOTOMY; PROSPECTIVE STUDIES; SAFETY; SURVIVORS; TRANSFERRIN;

EID: 2942538184     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.03264.x     Document Type: Article

References (19)

1. Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci 2000;319:73-8.
2. Parkkila S, Niemela O, Savolainen ER, Koistinen P. HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion 2001;41:828-31.
3. Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A. Secondary hemochromatosis as a long-term complication of the treatment of hematological malignancies. Am J Hematol 1999;61:262-4.
4. Mckay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996;17:63-6.
5. Or R, Matzner Y, Konjin AM. Serum ferritin in patients undergoing bone marrow transplantation. Cancer 1987;60:1127-31.
6. Franchini M, Gandini G, Aprili G. Advances in iron chelating therapy. Haematologica 2000;85:1122.
7. Borgna-Pignatti C, Franchini M, Gandini G, et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematological diseases and iron overload. Haematologica 1998;83:788-90.
8. Franchini M, Gandini G, de Gironcoli M, et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000;95:2776-9.
9. Bennet JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
10. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoid acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.
11. Todeschini G, Meneghini V, Pizzolo G, et al. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994;8:376-81.
12. Mandelli F, Petti MC, Ardia A, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia: a multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 1991;27:750-5.
13. Franchini M, Gandini G, Veneri D, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update. Blood 2004;103:747-8.
14. Hannuksela J, Savolainen ER, Koistinen P, Parkkila S. Prevalence of HFE genotypes, C282Y and H63D in patients with hematologic disorders. Haematologica 2002;87:131-5.
15. Dorak MT, Burnett AK, Worwood M. Hemochromatosis genes in leukemia and lymphoma. Leuk Lymphoma 2002;43:467-77.
16. Dorak MT, Burnett AK, Worwod M, Sproul AM, Gibson BE. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood 1999;94:3957-8.
17. Gimferrer E, Nomdedeu J, Gich I, Barcelò MJ, Baiget M. Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia. Leuk Res 1999;23:597-8.
18. Cassanelli S, Pignatti E, Montosi G, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol 2001;34:523-8.
19. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-62.